Maxygen Licensing Arrangement With Cangene Expires
Maxygen and Cangene have entered into an agreement in May 2009, under which Maxygen received from Cangene a non-refundable option fee of $500,000. As per the terms of
Faeth Therapeutics has received the US Food and Drug Administration’s (FDA) fast track designation for the sapanisertib and serabelisib (PIKTOR) with paclitaxel combination to treat advanced or recurrent endometrial cancer.